JamJam Therapeutics has secured bridge investments from Smilegate Investment and MYSC to enhance its AI-based rehabilitation solutions for children with disabilities and expand into global markets.

Target Information

JamJam Therapeutics, a company specializing in AI-based rehabilitation solutions for children with disabilities, has successfully secured bridge investments from Smilegate Investment and MYSC. Although the exact investment amount has not been disclosed, the company aims to utilize these funds to enhance its technology development and clinical research, establishing a strong foundation for entering global markets.

JamJam Therapeutics has developed the 'JamJam400', an AI motion recognition-based rehabilitation game that allows children with disabilities to conduct rehabilitation exercises without specialized equipment. Utilizing advanced AI technology, this solution analyzes hand and finger movements to deliver personalized rehabilitation activities. Clinical studies in collaboration with Catholic University have demonstrated that JamJam400 provides the same therapeutic effects as conventional glove-based hardware solutions, achieving a remarkable 22-fold reduction in treatment costs and a 13-fold increase in the frequency of exercise sessions, allowing for 380 sessions based on the cost of a single in-person treatment. The application is readily available for download on both the App Store and Google Play, significantly increasing accessibility for rehabilitation exercises.

Industry Overview

The rehabilitation technology industry in South Korea is rapidly evolving, driven by advancements in artificial intelligence and an increasing demand for accessible health solutions for various patient demogr